Journal of Clinical Oncology
Articles in this Issue
Qualitative assessment of barriers and facilitators of vagina dilator use after pelvic radiotherapy in a tertiary cancer centre in Nigeria.
e23262 Background: Pelvic radiotherapy (PRT) is an essential component of curative treatment for many gynaecological cance...
Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in recurrent platinum-resistant ovarian cancer: A real-world study.
e17595 Background: The role of immunotherapy in ovarian cancer remains poorly defined, with limited activity observed for...
Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).
1016 Background: evERA BC (NCT05306340) is the first Phase III trial to demonstrate a statistically significant and clinic...
Cost-effectiveness analysis of first-line (1L) therapies for advanced urothelial carcinoma (aUC) from a U.S. payer perspective.
4589 Background: Recent years have seen a shift in aUC management following approval of enfortumab vedotin–pembrolizumab (...
Dual immune checkpoint inhibition vs anti–PD-1 monotherapy in metastatic <i>BRAF</i> wild-type/undetermined melanoma: Ethnicity-based benchmarking of treatment endpoints in 2,659 patients.
e21512 Background: Immunotherapy is the mainstay for metastatic melanoma (MM), yet ethnic differences in treatment outcome...
Burden and survival outcome of secondary malignancies in Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL): A population-based analysis using Surveillance, Epidemiology, and End Results (SEER 2000-2022).
e19094 Background: WM/LPL is an indolent B-cell Non-Hodgkin Lymphoma with prolonged survival and predisposition to seconda...
Sex-stratified risk of second malignancies in Hodgkin lymphoma survivors: A retrospective study.
e19041 Background: Hodgkin lymphoma (HL) survivors are at increased risk of second primary malignancies (SPMs), often rela...
Clinical efficacy of laparoscopic hybrid surgery versus total open surgery for simultaneous resection of colorectal cancer liver metastases (CHLH trial).
3587 Background: Despite widespread adoption of simultaneous resection for colorectal liver metastases, the clinical effic...
Trends in early-onset colorectal cancer incidence (2000–2022) among Black Americans and Sub-Saharan African populations.
e15692 Background: Early-onset (age < 50) colorectal cancer (CRC) incidence is rising in low- and middle-income countri...
First-in-human evaluation and preclinical mechanistic studies of targeted hyperthermia therapy.
2595 Background: Photothermal conversion of near-infrared (NIR) light using specifically tuned, directly delivered gold na...
Association of <i>ESR1</i> amplification with survival and benefit from CDK4/6 inhibition in breast cancer.
1093 Background: While ESR1 mutations are established mediators of endocrine resistance in breast cancer (BC), the signifi...
Chemotherapy-induced gut microbiota taxonomic deviation and its association with outcomes and toxicities in breast cancer: CANTO microbiota.
2589 Background: Gut microbiota (GM) modulates immunotherapy (IT) efficacy and toxicity, but its impact on outcomes in bre...
High expression of CIITA, the master MHC-II regulator, as a predictor of survival benefit from immune checkpoint inhibitors across solid tumors.
e14589 Background: The class II major histocompatibility complex transactivator (CIITA) is the master regulator of MHC cla...
Clinical utility of discordances between histomorphology and molecular biomarkers in precision oncology.
3005 Background: Conventional molecular biomarkers guide treatment selection in precision oncology, yet therapeutic benefi...
Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis.
e17643 Background: Prognostic stratification of endometrial cancer has improved with the incorporation of molecular classi...
Pan-cancer analysis of STAT6 expression and its relationship with tumor microenvironment characteristics and survival.
2585 Background: Co-targetable immune pathways influence cancer outcomes and responses to immune checkpoint inhibitors (IC...
LAP-NET1: Results of a phase 1b evaluating NP137, an inhibitor of the epithelial-to-mesenchymal transition, in combination with mFOLFIRINOX for the first-line treatment of locally advanced pancreatic ductal adenocarcinoma.
4197 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by aggressive tumor d...
Utilizing a resident-led elective to improve the understanding of cancer prevention and survivorship among internal medicine residents.
e21006 Background: Advances in cancer screening, early detection, and targeted therapies have increased the number of canc...
Association between resilience and financial toxicity: The role of age, education, and health insurance.
e24124 Background: Women with metastatic breast cancer (MBC) are at high risk of financial toxicity (i.e., disturbed finan...
Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient’s whole blood.
e12505 Background: Despite no evidence of disease radiologically or pathologically, about 25-50% colorectal (CRC) Stage II...
Clinical impact and molecular profiling of <i>PTEN</i> loss and <i>TMPRSS2:ERG</i> fusion in metastatic hormone-sensitive prostate cancer.
5101 Background: PTEN loss in prostate cancer (PC) is associated with aggressive disease and resistanc...
SYS6010 combined with SYH2051 in advanced solid tumors: Results from a phase Ib/II trial.
4044 Background: SYS6010 is an antibody-drug conjugate (ADC) composed of an epidermal growth factor receptor (EGFR)-specif...
Real-world utilization patterns and adverse events among patients receiving antibody–drug conjugates (ADCs) across the University of California health system.
11118 Background: Antibody–drug conjugates (ADCs) have rapidly expanded across oncology indications, yet real-world safety...
Barriers and variability in lymphedema therapy for head and neck cancer survivors: Secondary analysis from a randomized trial.
6108 Background: Secondary lymphedema is a significant underrecognized sequela of head and neck cancer (HNC) and its treat...
Epidemiological trends and burden of esophageal cancer in the United States, 1990–2023: A retrospective analysis with machine learning projections to 2050.
e16058 Background: Esophageal cancer remains a significant cause of cancer-related mortality in the United States, with ri...